Keywords: Sanofi, Lyxumia, Zaltap, Novartis, Bexsero, Celgen, Istodax, CHMP recommendations, Type 2 diabets, Colorectal cancer, Meningococcal B vaccine, Lymphoma
Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene
Article | 19 November 2012
There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
